Literature DB >> 19089566

Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.

Kenji Yamashiro1,2,3, Akitaka Tsujikawa4, Akihiro Nishida5,6, Michiko Mandai5,7, Yasuo Kurimoto5,6.   

Abstract

PURPOSE: To evaluate the recurrence of polypoidal lesions after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).
METHODS: This is a retrospective review of data on 28 patients with PCV treated with PDT. The recurrent polypoidal lesions were observed with fluorescein and indocyanine green angiography.
RESULTS: In 26 of the 28 eyes the PCV remained inactive for more than 12 months after one to three treatments with PDT. Recurrence of the polypoidal lesions after more than a 12-month inactive period was reported in eight eyes: three at 15 months, two at 18 months, and three at 21 months. Kaplan-Meier estimates of recurrence were 11.5% at 15 months, 20.4% at 18 months, and 38.8% at 21 months, with no subsequent recurrence until passage of 36 months of inactivity after the last PDT. Additional PDT after recurrence improved or preserved visual acuity in 80% of those treated compared to the visual acuity before the first PDT.
CONCLUSIONS: Recurrence of PCV occurs in about 40% of eyes treated for PCV even after a long period of inactivity, so careful follow-up is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19089566     DOI: 10.1007/s10384-008-0582-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  24 in total

1.  Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.

Authors:  M Mauget-Faÿsse; M Quaranta-El Maftouhi; E De La Marnièrre; A Leys
Journal:  Eur J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.597

2.  Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin.

Authors:  Kaori Sayanagi; Fumi Gomi; Miki Sawa; Masahito Ohji; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

3.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

5.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Nazimul Hussain; Anjli Hussain; Sundaram Natarajan
Journal:  Indian J Ophthalmol       Date:  2005-06       Impact factor: 1.848

6.  An update on multiple recurrent serosanguineous retinal pigment epithelial detachments in black women.

Authors:  B T Perkovich; Z N Zakov; L A Berlin; D Weidenthal; L R Avins
Journal:  Retina       Date:  1990       Impact factor: 4.256

7.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

8.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

9.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

10.  Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroko Aikawa; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-04-30       Impact factor: 5.258

View more
  8 in total

1.  Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Authors:  Isao Nakata; Akitaka Tsujikawa; Kenji Yamashiro; Atsushi Otani; Sotaro Ooto; Yumiko Akagi-Kurashige; Naoko Ueda-Arakawa; Daisuke Iwama; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-25       Impact factor: 3.117

2.  Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yukinori Sugano; Tomohiro Iida; Ichiro Maruko; Akira Ojima; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2013-02-14       Impact factor: 2.447

3.  Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Masahiro Miyake; Kenji Yamashiro; Sotaro Ooto; Akio Oishi; Isao Nakata; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-30       Impact factor: 3.117

4.  Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yusaku Yoshida; Takeya Kohno; Manabu Yamamoto; Tasuku Yoneda; Hisashi Iwami; Kunihiko Shiraki
Journal:  Jpn J Ophthalmol       Date:  2013-02-15       Impact factor: 2.447

5.  Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.

Authors:  Mitsuhiro Imasawa; Toyoaki Tsumura; Arata Sekine; Toyohiko Kikuchi; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

6.  Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Authors:  Mitsuhiro Imasawa; Yoichi Sakurada; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2011-05-11       Impact factor: 2.447

7.  Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment.

Authors:  Ju Byung Chae; Joo Yong Lee; Sung Jae Yang; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2011-03-11

Review 8.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.